CLL-1 CAR-T has been proposed as a consolidation strategy for AML in remission, as CLL-1 positive blast cells are relatively chemotherapy resistant and this approach reduced relapse in a xenograft model [51]. This evidence concerns the gene CLEC12A and acute myeloid leukemia.